世界の乳がん用ジェネリック医薬品市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Breast Cancer Generic Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0989 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、乳がん用ジェネリック医薬品のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（レトロゾール、アナストロゾール、エキセメスタン、エピルビシン、トレミフェン、フルベストラント、メゲストロール（ホスピーラ））、用途別市場規模（乳管癌、浸潤性乳管癌、小葉癌、トリプルネガティブ乳がん）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・乳がん用ジェネリック医薬品の市場動向 ・企業の競争状況、市場シェア ・乳がん用ジェネリック医薬品の種類別市場規模（レトロゾール、アナストロゾール、エキセメスタン、エピルビシン、トレミフェン、フルベストラント、メゲストロール（ホスピーラ）） ・乳がん用ジェネリック医薬品の用途別市場規模（乳管癌、浸潤性乳管癌、小葉癌、トリプルネガティブ乳がん） ・乳がん用ジェネリック医薬品の北米市場規模2016-2027（アメリカ、カナダ） ・乳がん用ジェネリック医薬品のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・乳がん用ジェネリック医薬品のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・乳がん用ジェネリック医薬品の中南米市場規模2016-2027（メキシコ、ブラジル） ・乳がん用ジェネリック医薬品の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Teva、Mylan、Fresenius Kabi、Endo、Apotex、Sun Pharma、Hengrui、Novartis、Taro、Arab Pharmaceutical、Yiling Pharmaceutical、Hikma Pharmaceuticals、Dr. Reddy's Laboratories、Natco Pharma、Cipla、Accord Healthcare） ・結論

Market Analysis and Insights: Global Breast Cancer Generic Drugs Market
The global Breast Cancer Generic Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Breast Cancer Generic Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Breast Cancer Generic Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Breast Cancer Generic Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Breast Cancer Generic Drugs market.

Global Breast Cancer Generic Drugs Scope and Market Size
Breast Cancer Generic Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Breast Cancer Generic Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Letrozole
Anastrazole
Exemestane
Epirubicine
Toremifene
Fulvestrant
Megestrol (Hospira)

Segment by Application
Ductal Carcinoma of Breast
Invasive Ductal Carcinoma
Lobular Carcinoma
Triple Negative Breast Cancer

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Teva
Mylan
Fresenius Kabi
Endo
Apotex
Sun Pharma
Hengrui
Novartis
Taro
Endo
Apotex
Hikma Pharmaceuticals
Dr. Reddy’s Laboratories
Natco Pharma

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Breast Cancer Generic Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Letrozole
1.2.3 Anastrazole
1.2.4 Exemestane
1.2.5 Epirubicine
1.2.6 Toremifene
1.2.7 Fulvestrant
1.2.8 Megestrol (Hospira)
1.3 Market by Application
1.3.1 Global Breast Cancer Generic Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Ductal Carcinoma of Breast
1.3.3 Invasive Ductal Carcinoma
1.3.4 Lobular Carcinoma
1.3.5 Triple Negative Breast Cancer
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Breast Cancer Generic Drugs Market Perspective (2016-2027)
2.2 Breast Cancer Generic Drugs Growth Trends by Regions
2.2.1 Breast Cancer Generic Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Breast Cancer Generic Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Breast Cancer Generic Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Breast Cancer Generic Drugs Industry Dynamic
2.3.1 Breast Cancer Generic Drugs Market Trends
2.3.2 Breast Cancer Generic Drugs Market Drivers
2.3.3 Breast Cancer Generic Drugs Market Challenges
2.3.4 Breast Cancer Generic Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Breast Cancer Generic Drugs Players by Revenue
3.1.1 Global Top Breast Cancer Generic Drugs Players by Revenue (2016-2021)
3.1.2 Global Breast Cancer Generic Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Breast Cancer Generic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Breast Cancer Generic Drugs Revenue
3.4 Global Breast Cancer Generic Drugs Market Concentration Ratio
3.4.1 Global Breast Cancer Generic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Breast Cancer Generic Drugs Revenue in 2020
3.5 Breast Cancer Generic Drugs Key Players Head office and Area Served
3.6 Key Players Breast Cancer Generic Drugs Product Solution and Service
3.7 Date of Enter into Breast Cancer Generic Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Breast Cancer Generic Drugs Breakdown Data by Type
4.1 Global Breast Cancer Generic Drugs Historic Market Size by Type (2016-2021)
4.2 Global Breast Cancer Generic Drugs Forecasted Market Size by Type (2022-2027)

5 Breast Cancer Generic Drugs Breakdown Data by Application
5.1 Global Breast Cancer Generic Drugs Historic Market Size by Application (2016-2021)
5.2 Global Breast Cancer Generic Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Breast Cancer Generic Drugs Market Size (2016-2027)
6.2 North America Breast Cancer Generic Drugs Market Size by Type
6.2.1 North America Breast Cancer Generic Drugs Market Size by Type (2016-2021)
6.2.2 North America Breast Cancer Generic Drugs Market Size by Type (2022-2027)
6.2.3 North America Breast Cancer Generic Drugs Market Size by Type (2016-2027)
6.3 North America Breast Cancer Generic Drugs Market Size by Application
6.3.1 North America Breast Cancer Generic Drugs Market Size by Application (2016-2021)
6.3.2 North America Breast Cancer Generic Drugs Market Size by Application (2022-2027)
6.3.3 North America Breast Cancer Generic Drugs Market Size by Application (2016-2027)
6.4 North America Breast Cancer Generic Drugs Market Size by Country
6.4.1 North America Breast Cancer Generic Drugs Market Size by Country (2016-2021)
6.4.2 North America Breast Cancer Generic Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Breast Cancer Generic Drugs Market Size (2016-2027)
7.2 Europe Breast Cancer Generic Drugs Market Size by Type
7.2.1 Europe Breast Cancer Generic Drugs Market Size by Type (2016-2021)
7.2.2 Europe Breast Cancer Generic Drugs Market Size by Type (2022-2027)
7.2.3 Europe Breast Cancer Generic Drugs Market Size by Type (2016-2027)
7.3 Europe Breast Cancer Generic Drugs Market Size by Application
7.3.1 Europe Breast Cancer Generic Drugs Market Size by Application (2016-2021)
7.3.2 Europe Breast Cancer Generic Drugs Market Size by Application (2022-2027)
7.3.3 Europe Breast Cancer Generic Drugs Market Size by Application (2016-2027)
7.4 Europe Breast Cancer Generic Drugs Market Size by Country
7.4.1 Europe Breast Cancer Generic Drugs Market Size by Country (2016-2021)
7.4.2 Europe Breast Cancer Generic Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Breast Cancer Generic Drugs Market Size (2016-2027)
8.2 Asia-Pacific Breast Cancer Generic Drugs Market Size by Type
8.2.1 Asia-Pacific Breast Cancer Generic Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Breast Cancer Generic Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Breast Cancer Generic Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Breast Cancer Generic Drugs Market Size by Application
8.3.1 Asia-Pacific Breast Cancer Generic Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Breast Cancer Generic Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Breast Cancer Generic Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Breast Cancer Generic Drugs Market Size by Region
8.4.1 Asia-Pacific Breast Cancer Generic Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Breast Cancer Generic Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Breast Cancer Generic Drugs Market Size (2016-2027)
9.2 Latin America Breast Cancer Generic Drugs Market Size by Type
9.2.1 Latin America Breast Cancer Generic Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Breast Cancer Generic Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Breast Cancer Generic Drugs Market Size by Type (2016-2027)
9.3 Latin America Breast Cancer Generic Drugs Market Size by Application
9.3.1 Latin America Breast Cancer Generic Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Breast Cancer Generic Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Breast Cancer Generic Drugs Market Size by Application (2016-2027)
9.4 Latin America Breast Cancer Generic Drugs Market Size by Country
9.4.1 Latin America Breast Cancer Generic Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Breast Cancer Generic Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Breast Cancer Generic Drugs Market Size (2016-2027)
10.2 Middle East & Africa Breast Cancer Generic Drugs Market Size by Type
10.2.1 Middle East & Africa Breast Cancer Generic Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Breast Cancer Generic Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Breast Cancer Generic Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Breast Cancer Generic Drugs Market Size by Application
10.3.1 Middle East & Africa Breast Cancer Generic Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Breast Cancer Generic Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Breast Cancer Generic Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Breast Cancer Generic Drugs Market Size by Country
10.4.1 Middle East & Africa Breast Cancer Generic Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Breast Cancer Generic Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Details
11.1.2 Teva Business Overview
11.1.3 Teva Breast Cancer Generic Drugs Introduction
11.1.4 Teva Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.1.5 Teva Recent Development
11.2 Mylan
11.2.1 Mylan Company Details
11.2.2 Mylan Business Overview
11.2.3 Mylan Breast Cancer Generic Drugs Introduction
11.2.4 Mylan Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.2.5 Mylan Recent Development
11.3 Fresenius Kabi
11.3.1 Fresenius Kabi Company Details
11.3.2 Fresenius Kabi Business Overview
11.3.3 Fresenius Kabi Breast Cancer Generic Drugs Introduction
11.3.4 Fresenius Kabi Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.3.5 Fresenius Kabi Recent Development
11.4 Endo
11.4.1 Endo Company Details
11.4.2 Endo Business Overview
11.4.3 Endo Breast Cancer Generic Drugs Introduction
11.4.4 Endo Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.4.5 Endo Recent Development
11.5 Apotex
11.5.1 Apotex Company Details
11.5.2 Apotex Business Overview
11.5.3 Apotex Breast Cancer Generic Drugs Introduction
11.5.4 Apotex Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.5.5 Apotex Recent Development
11.6 Sun Pharma
11.6.1 Sun Pharma Company Details
11.6.2 Sun Pharma Business Overview
11.6.3 Sun Pharma Breast Cancer Generic Drugs Introduction
11.6.4 Sun Pharma Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.6.5 Sun Pharma Recent Development
11.7 Hengrui
11.7.1 Hengrui Company Details
11.7.2 Hengrui Business Overview
11.7.3 Hengrui Breast Cancer Generic Drugs Introduction
11.7.4 Hengrui Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.7.5 Hengrui Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Breast Cancer Generic Drugs Introduction
11.8.4 Novartis Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.8.5 Novartis Recent Development
11.9 Taro
11.9.1 Taro Company Details
11.9.2 Taro Business Overview
11.9.3 Taro Breast Cancer Generic Drugs Introduction
11.9.4 Taro Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.9.5 Taro Recent Development
11.10 Arab Pharmaceutical
11.10.1 Arab Pharmaceutical Company Details
11.10.2 Arab Pharmaceutical Business Overview
11.10.3 Arab Pharmaceutical Breast Cancer Generic Drugs Introduction
11.10.4 Arab Pharmaceutical Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.10.5 Arab Pharmaceutical Recent Development
11.11 Yiling Pharmaceutical
11.11.1 Yiling Pharmaceutical Company Details
11.11.2 Yiling Pharmaceutical Business Overview
11.11.3 Yiling Pharmaceutical Breast Cancer Generic Drugs Introduction
11.11.4 Yiling Pharmaceutical Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.11.5 Yiling Pharmaceutical Recent Development
11.12 Hikma Pharmaceuticals
11.12.1 Hikma Pharmaceuticals Company Details
11.12.2 Hikma Pharmaceuticals Business Overview
11.12.3 Hikma Pharmaceuticals Breast Cancer Generic Drugs Introduction
11.12.4 Hikma Pharmaceuticals Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.12.5 Hikma Pharmaceuticals Recent Development
11.13 Dr. Reddy’s Laboratories
11.13.1 Dr. Reddy’s Laboratories Company Details
11.13.2 Dr. Reddy’s Laboratories Business Overview
11.13.3 Dr. Reddy’s Laboratories Breast Cancer Generic Drugs Introduction
11.13.4 Dr. Reddy’s Laboratories Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.13.5 Dr. Reddy’s Laboratories Recent Development
11.14 Natco Pharma
11.14.1 Natco Pharma Company Details
11.14.2 Natco Pharma Business Overview
11.14.3 Natco Pharma Breast Cancer Generic Drugs Introduction
11.14.4 Natco Pharma Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.14.5 Natco Pharma Recent Development
11.15 Cipla
11.15.1 Cipla Company Details
11.15.2 Cipla Business Overview
11.15.3 Cipla Breast Cancer Generic Drugs Introduction
11.15.4 Cipla Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.15.5 Cipla Recent Development
11.16 Accord Healthcare
11.16.1 Accord Healthcare Company Details
11.16.2 Accord Healthcare Business Overview
11.16.3 Accord Healthcare Breast Cancer Generic Drugs Introduction
11.16.4 Accord Healthcare Revenue in Breast Cancer Generic Drugs Business (2016-2021)
11.16.5 Accord Healthcare Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Breast Cancer Generic Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Letrozole
Table 3. Key Players of Anastrazole
Table 4. Key Players of Exemestane
Table 5. Key Players of Epirubicine
Table 6. Key Players of Toremifene
Table 7. Key Players of Fulvestrant
Table 8. Key Players of Megestrol (Hospira)
Table 9. Global Breast Cancer Generic Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Breast Cancer Generic Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Breast Cancer Generic Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Breast Cancer Generic Drugs Market Share by Regions (2016-2021)
Table 13. Global Breast Cancer Generic Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Breast Cancer Generic Drugs Market Share by Regions (2022-2027)
Table 15. Breast Cancer Generic Drugs Market Trends
Table 16. Breast Cancer Generic Drugs Market Drivers
Table 17. Breast Cancer Generic Drugs Market Challenges
Table 18. Breast Cancer Generic Drugs Market Restraints
Table 19. Global Breast Cancer Generic Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Breast Cancer Generic Drugs Market Share by Players (2016-2021)
Table 21. Global Top Breast Cancer Generic Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Breast Cancer Generic Drugs as of 2020)
Table 22. Ranking of Global Top Breast Cancer Generic Drugs Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Breast Cancer Generic Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Breast Cancer Generic Drugs Product Solution and Service
Table 26. Date of Enter into Breast Cancer Generic Drugs Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Breast Cancer Generic Drugs Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Breast Cancer Generic Drugs Revenue Market Share by Type (2016-2021)
Table 30. Global Breast Cancer Generic Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Breast Cancer Generic Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Breast Cancer Generic Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Breast Cancer Generic Drugs Revenue Market Share by Application (2016-2021)
Table 34. Global Breast Cancer Generic Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Breast Cancer Generic Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Breast Cancer Generic Drugs Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Breast Cancer Generic Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Breast Cancer Generic Drugs Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Breast Cancer Generic Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Breast Cancer Generic Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Breast Cancer Generic Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Breast Cancer Generic Drugs Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Breast Cancer Generic Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Breast Cancer Generic Drugs Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Breast Cancer Generic Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Breast Cancer Generic Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Breast Cancer Generic Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Breast Cancer Generic Drugs Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Breast Cancer Generic Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Breast Cancer Generic Drugs Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Breast Cancer Generic Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Breast Cancer Generic Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Breast Cancer Generic Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Breast Cancer Generic Drugs Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Breast Cancer Generic Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Breast Cancer Generic Drugs Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Breast Cancer Generic Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Breast Cancer Generic Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Breast Cancer Generic Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Breast Cancer Generic Drugs Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Breast Cancer Generic Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Breast Cancer Generic Drugs Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Breast Cancer Generic Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Breast Cancer Generic Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Breast Cancer Generic Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 66. Teva Company Details
Table 67. Teva Business Overview
Table 68. Teva Breast Cancer Generic Drugs Product
Table 69. Teva Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 70. Teva Recent Development
Table 71. Mylan Company Details
Table 72. Mylan Business Overview
Table 73. Mylan Breast Cancer Generic Drugs Product
Table 74. Mylan Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 75. Mylan Recent Development
Table 76. Fresenius Kabi Company Details
Table 77. Fresenius Kabi Business Overview
Table 78. Fresenius Kabi Breast Cancer Generic Drugs Product
Table 79. Fresenius Kabi Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 80. Fresenius Kabi Recent Development
Table 81. Endo Company Details
Table 82. Endo Business Overview
Table 83. Endo Breast Cancer Generic Drugs Product
Table 84. Endo Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 85. Endo Recent Development
Table 86. Apotex Company Details
Table 87. Apotex Business Overview
Table 88. Apotex Breast Cancer Generic Drugs Product
Table 89. Apotex Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 90. Apotex Recent Development
Table 91. Sun Pharma Company Details
Table 92. Sun Pharma Business Overview
Table 93. Sun Pharma Breast Cancer Generic Drugs Product
Table 94. Sun Pharma Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 95. Sun Pharma Recent Development
Table 96. Hengrui Company Details
Table 97. Hengrui Business Overview
Table 98. Hengrui Breast Cancer Generic Drugs Product
Table 99. Hengrui Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 100. Hengrui Recent Development
Table 101. Novartis Company Details
Table 102. Novartis Business Overview
Table 103. Novartis Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 104. Novartis Recent Development
Table 105. Taro Company Details
Table 106. Taro Business Overview
Table 107. Taro Breast Cancer Generic Drugs Product
Table 108. Taro Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 109. Taro Recent Development
Table 110. Arab Pharmaceutical Company Details
Table 111. Arab Pharmaceutical Business Overview
Table 112. Arab Pharmaceutical Breast Cancer Generic Drugs Product
Table 113. Arab Pharmaceutical Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 114. Arab Pharmaceutical Recent Development
Table 115. Yiling Pharmaceutical Company Details
Table 116. Yiling Pharmaceutical Business Overview
Table 117. Yiling Pharmaceutical Breast Cancer Generic Drugs Product
Table 118. Yiling Pharmaceutical Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 119. Yiling Pharmaceutical Recent Development
Table 120. Hikma Pharmaceuticals Company Details
Table 121. Hikma Pharmaceuticals Business Overview
Table 122. Hikma Pharmaceuticals Breast Cancer Generic Drugs Product
Table 123. Hikma Pharmaceuticals Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 124. Hikma Pharmaceuticals Recent Development
Table 125. Dr. Reddy's Laboratories Company Details
Table 126. Dr. Reddy's Laboratories Business Overview
Table 127. Dr. Reddy's Laboratories Breast Cancer Generic Drugs Product
Table 128. Dr. Reddy's Laboratories Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 129. Dr. Reddy's Laboratories Recent Development
Table 130. Natco Pharma Company Details
Table 131. Natco Pharma Business Overview
Table 132. Natco Pharma Breast Cancer Generic Drugs Product
Table 133. Natco Pharma Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 134. Natco Pharma Recent Development
Table 135. Cipla Company Details
Table 136. Cipla Business Overview
Table 137. Cipla Breast Cancer Generic Drugs Product
Table 138. Cipla Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 139. Cipla Recent Development
Table 140. Accord Healthcare Company Details
Table 141. Accord Healthcare Business Overview
Table 142. Accord Healthcare Breast Cancer Generic Drugs Product
Table 143. Accord Healthcare Revenue in Breast Cancer Generic Drugs Business (2016-2021) & (US$ Million)
Table 144. Accord Healthcare Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Breast Cancer Generic Drugs Market Share by Type: 2020 VS 2027
Figure 2. Letrozole Features
Figure 3. Anastrazole Features
Figure 4. Exemestane Features
Figure 5. Epirubicine Features
Figure 6. Toremifene Features
Figure 7. Fulvestrant Features
Figure 8. Megestrol (Hospira) Features
Figure 9. Global Breast Cancer Generic Drugs Market Share by Application: 2020 VS 2027
Figure 10. Ductal Carcinoma of Breast Case Studies
Figure 11. Invasive Ductal Carcinoma Case Studies
Figure 12. Lobular Carcinoma Case Studies
Figure 13. Triple Negative Breast Cancer Case Studies
Figure 14. Breast Cancer Generic Drugs Report Years Considered
Figure 15. Global Breast Cancer Generic Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Breast Cancer Generic Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Breast Cancer Generic Drugs Market Share by Regions: 2020 VS 2027
Figure 18. Global Breast Cancer Generic Drugs Market Share by Regions (2022-2027)
Figure 19. Global Breast Cancer Generic Drugs Market Share by Players in 2020
Figure 20. Global Top Breast Cancer Generic Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Breast Cancer Generic Drugs as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Breast Cancer Generic Drugs Revenue in 2020
Figure 22. Global Breast Cancer Generic Drugs Revenue Market Share by Type (2016-2021)
Figure 23. Global Breast Cancer Generic Drugs Revenue Market Share by Type (2022-2027)
Figure 24. North America Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Breast Cancer Generic Drugs Market Share by Type (2016-2027)
Figure 26. North America Breast Cancer Generic Drugs Market Share by Application (2016-2027)
Figure 27. North America Breast Cancer Generic Drugs Market Share by Country (2016-2027)
Figure 28. United States Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Breast Cancer Generic Drugs Market Share by Type (2016-2027)
Figure 32. Europe Breast Cancer Generic Drugs Market Share by Application (2016-2027)
Figure 33. Europe Breast Cancer Generic Drugs Market Share by Country (2016-2027)
Figure 34. Germany Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Breast Cancer Generic Drugs Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Breast Cancer Generic Drugs Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Breast Cancer Generic Drugs Market Share by Region (2016-2027)
Figure 44. China Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Breast Cancer Generic Drugs Market Share by Type (2016-2027)
Figure 52. Latin America Breast Cancer Generic Drugs Market Share by Application (2016-2027)
Figure 53. Latin America Breast Cancer Generic Drugs Market Share by Country (2016-2027)
Figure 54. Mexico Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Breast Cancer Generic Drugs Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Breast Cancer Generic Drugs Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Breast Cancer Generic Drugs Market Share by Country (2016-2027)
Figure 60. Turkey Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Breast Cancer Generic Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Teva Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 64. Mylan Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 65. Fresenius Kabi Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 66. Endo Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 67. Apotex Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 68. Sun Pharma Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 69. Hengrui Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 70. Novartis Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 71. Taro Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 72. Arab Pharmaceutical Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 73. Yiling Pharmaceutical Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 74. Hikma Pharmaceuticals Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 75. Dr. Reddy's Laboratories Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 76. Natco Pharma Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 77. Cipla Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 78. Accord Healthcare Revenue Growth Rate in Breast Cancer Generic Drugs Business (2016-2021)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed

---